Some 20 percent of 650 clinical germlines analyzed since the project launched last year have had at least one variant associated with increased cancer risk.
Researchers led by MIT's Jim Collins have built upon their paper-based Ebola test and are hoping to find a partner to help scale production and manufacturing of the test.
In addition to the hepatitis C panel, the company offers a number of next-generation sequencing-based tests including one for colorectal cancer.
The company is developing a proteomic test for chronic obstructive pulmonary disease that it plans to launch in early 2018 as a CLIA-based diagnostic.
The startup will use the fund to begin commercialization of its PCR-based VerifyDx prostate cancer test.
In Science this week: CRISPR-based approach to identify gene variants, and more.
Stat News profiles the Wellcome Trust's Jeremy Farrar.
France's research minister tells Nature News that he hopes to simplify the research bureaucracy and improve funding.
A recent study examines how a paper, despite being retracted, can influence its field, Retraction Watch reports.